We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
-2.75%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$14.1B
AUM Growth
+$273M
Cap. Flow
-$650M
Cap. Flow %
-4.61%
Top 10 Hldgs %
32.88%
Holding
703
New
–
Increased
221
Reduced
319
Closed
43

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$41.6M
2
NVDA icon
NVIDIA
NVDA
+$36M
3
ISRG icon
Intuitive Surgical
ISRG
+$33.8M
4
AMAT icon
Applied Materials
AMAT
+$32.4M
5
XP icon
XP
XP
+$31M

Top Sells

Rank Stock Value
1
V icon
Visa
V
+$57.8M
2
JNJ icon
Johnson & Johnson
JNJ
+$54.9M
3
DHR icon
Danaher
DHR
+$41.9M
4
MSFT icon
Microsoft
MSFT
+$40.7M
5
LRCX icon
Lam Research
LRCX
+$37.4M

Sector Composition

Rank Sector Weight
1 Healthcare 26.08%
2 Technology 25.64%
3 Financials 11.81%
4 Industrials 7.9%
5 Materials 7.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLK icon
276
Blackrock
BLK
$167B
$6.57M 0.05%
10,158
-186
-2% -$130K
RNR icon
277
RenaissanceRe
RNR
$13.8B
$6.55M 0.05%
33,105
-2,817
-8% -$542K
BNTX icon
278
BioNTech
BNTX
$23.5B
$6.55M 0.05%
60,303
-82,000
-58% -$9.07M
PTCT icon
279
PTC Therapeutics
PTCT
$6.18B
$6.54M 0.05%
291,652
– –
DYN icon
280
Dyne Therapeutics
DYN
$4.15B
$6.48M 0.05%
723,624
– –
BBIO icon
281
BridgeBio Pharma
BBIO
$16.4B
$6.46M 0.05%
245,000
-40,000
-14% -$1.14M
PHR icon
282
Phreesia
PHR
$689M
$6.43M 0.05%
344,168
+274,168
+392% +$7.38M
CI icon
283
Cigna
CI
$78.4B
$6.42M 0.05%
22,450
-728
-3% -$208K
BILL icon
284
BILL Holdings
BILL
$4.72B
$6.36M 0.05%
58,549
+3,976
+7% +$452K
GTLS
285
DELISTED
Chart Industries
GTLS
$6.35M 0.05%
37,537
– –
KURA icon
286
Kura Oncology
KURA
$793M
$6.31M 0.04%
691,422
– –
MCO icon
287
Moody's
MCO
$83.7B
$6.13M 0.04%
19,393
+3,843
+25% +$1.31M
BMI icon
288
Badger Meter
BMI
$3.87B
$5.94M 0.04%
41,254
+32,737
+384% +$5.17M
ARWR icon
289
Arrowhead Research
ARWR
$12.1B
$5.91M 0.04%
220,054
– –
ES icon
290
Eversource Energy
ES
$28.1B
$5.79M 0.04%
99,591
-61,035
-38% -$4.07M
ZBH icon
291
Zimmer Biomet
ZBH
$18.8B
$5.74M 0.04%
51,165
+8,534
+20% +$1.08M
MORF
292
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$5.73M 0.04%
249,933
– –
CLX icon
293
Clorox
CLX
$12B
$5.62M 0.04%
42,866
+29,530
+221% +$4.49M
TMCI icon
294
Treace Medical Concepts
TMCI
$262M
$5.61M 0.04%
427,972
+357,972
+511% +$6.55M
ITOS
295
DELISTED
iTeos Therapeutics
ITOS
$5.6M 0.04%
511,537
-100,010
-16% -$1.28M
PLRX icon
296
Pliant Therapeutics
PLRX
$65M
$5.46M 0.04%
315,000
+50,000
+19% +$867K
STRO icon
297
Sutro Biopharma
STRO
$386M
$5.34M 0.04%
153,823
-9,000
-6% -$392K
OKTA icon
298
Okta
OKTA
$23.8B
$5.32M 0.04%
65,282
-4,483
-6% -$340K
BURL icon
299
Burlington
BURL
$23.4B
$5.31M 0.04%
39,239
+35,829
+1,051% +$5.75M
AKAM icon
300
Akamai
AKAM
$15.6B
$5.26M 0.04%
49,404
+2,126
+4% +$212K
10 11
12
13 14

Similar funds

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
A
AustralianSuper Melbourne, Australia $19.2B AUM 31.95% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $19.1B AUM 26.9% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return

Candriam SCA's Q3 2023 Portfolio in Review

As of Q3 2023, Candriam SCA held 703 positions worth $14.1B, up 2% from $13.8B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Candriam SCA withdrew a net $650M in Q3 2023, closing 43 positions and reducing 319 holdings. Its most notable exit was Chinook Therapeutics, Inc. Common Stock, an estimated $31.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 26% of assets, down from 31% a quarter earlier, followed by Technology and Financials.

Against the trend, Candriam SCA added an estimated $41.6M to Amgen.

  • Candriam SCA added most to Amgen in Q3 2023, an estimated $41.6M increase.
  • Candriam SCA's biggest Q3 2023 reduction was Visa, cutting an estimated $57.8M.
  • Candriam SCA fully exited Chinook Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $31.7M.
  • Candriam SCA's ten largest holdings make up 33% of its $14.1B portfolio in Q3 2023.
  • Candriam SCA opened 0 new positions and closed 43 in Q3 2023.
  • Candriam SCA's portfolio value rose 2% quarter-over-quarter to $14.1B.

Based on Candriam SCA's 13F filing for Q3 2023, filed 13 Nov 2023.